Short Term Trading Week Starting: 8th May, page-60

Yes GFM, the story could be quite amazing. Has all the ingredients for a Unicorn stock. I'm very long for Fuji outcome. Also has nice cash pot now of circa $12m.

It's a Biotech, but it's really an Enabling TECH for all Biotech companies involved with stem cell therapies.

It started moving again on the senior Fuji rep Toshi Ban doing a webinar with CYP MD and singing praises + 3 directors now purchasing in 40s

I took a trade at 40c again based on the TA reversal signal as mentioned on CYP thread.
Morning Star reverse. up 29% so far. It's a reliable signal with 78% success rate.

For those that want to read the full report: http://cynata.com/wp-content/uploads/2017/05/CR_DV_CYP_20170505_408b16c568034b13963b09ec14685e5f.pdf

Extract:

Investment view - BUY Since CYP acquired its Cymerus™ technology in 2013, significant clinical and pre-clinical developments - both its own and by external groups - have propelled the technology forward as the only likely viable MSC production technology for large scale clinical applications.

Our confidence that CYP’s technology will be disruptive to the global stem cell market, estimated to be worth US$100b p.a. in eight years (see page 6), is based on:
1. 600 + ongoing trials of stem cells and more specifically 493 trials of MSCs which have concluded MSC are efficacious in a wide range of diseases and conditions,
2. The substantial industry evidence now available highlighting loss of potency from traditional

MSC manufacturing methods once cells have been expanded beyond thirteen population doublings (see page 5), which represents a production problem that is preventing stem cells realising their commercial potential.
3. CYP’s pre-clinical program in vitro and in animal models has demonstrated the sterility, purity, potency, stability, safety and indicative efficacy of Cymerus™ MSCs.
4. In 2016 apceth1 and Regience 2 , both conducted independent due diligence on CYP’s MSCs and concluded that the key characteristics of cells produced using Cymerus, was highly satisfactory,
5. In 2017 Fujifilm, one of the largest global investors in stem cell technology, invested $US3mn in CYP at a 35% premium to CYP’s 6 month VWAP and partnered CYP’s CYP- 001 MSC product for prevention and treatment of GvHD worldwide,
6. The UK Medicines and Healthcare products Regulatory Agency trial approval validates CYP’s manufacturing and safety. The trial approval provides validation from one of the most highly regarded regulatory authorities in the world that CYP’s manufacturing process and preclinical development programs have established what it considers to be a product safe enough to be trialled in humans, and,
7. Waisman Biomanufacturing, CYP’s contract manufacturer, has established indicative efficacy using a range of assays 3 .


*FujiFilm took over CYP sister company for US$307m....so read what Fujis Toshi Ban said recently about both companies/techs. Fuji WILL need Cymerus to commerialise. Last piece of the jigsaw. DYOR.